Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
NCT06532578Phase 2Completed
- Sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CPX101 in obesity (5 cohorts), sponsored by Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. Primary endpoint: Body weight loss at 24 weeks. Started Aug 2024; status: completed.
02
Drugs
CPX101
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06532578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532578.